ERBB2 and breast carcinoma: Considering that of 9–30% of ovarian cancer patients were HER2 positive, and there are several similarities of the biology of HER2 between breast cancer and ovarian cancer, it would be feasible to treat ovarian cancer via HER2 target therapy [6,7].